Search hospitals > Utah > Salt Lake City
Huntsman Cancer Institute/University of Utah
Claim this profileSalt Lake City, Utah 84112
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Cancer
Conducts research for Uterine Tumors
1129 reported clinical trials
82 medical researchers
Summary
Huntsman Cancer Institute/University of Utah is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Skin Cancer, Breast Cancer, T-Lymphoblastic Leukemia/Lymphoma, Cancer, Uterine Tumors and other specialties. Huntsman Cancer Institute/University of Utah is involved with conducting 1,129 clinical trials across 829 conditions. There are 82 research doctors associated with this hospital, such as Heloisa Soares, Michael Pulsipher, MD, Sunil Sharma, and Theresa Werner, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Heloisa SoaresHuntsman Cancer Institute/University of Utah3 years of reported clinical research
Expert in Neuroendocrine Tumors
Studies Uterine Tumors
25 reported clinical trials
50 drugs studied
Michael Pulsipher, MDChildren's Hospital Los Angeles1 year of reported clinical research
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
17 reported clinical trials
32 drugs studied
Sunil SharmaHonorHealth Research Institute1 year of reported clinical research
Studies Skin Cancer
Studies Solid Tumors
16 reported clinical trials
34 drugs studied
Theresa Werner, MDHuntsman Cancer Institute/University of Utah2 years of reported clinical research
Studies Ovarian Cancer
Studies Stomach Cancer
14 reported clinical trials
23 drugs studied
Clinical Trials running at Huntsman Cancer Institute/University of Utah
Skin Cancer
Esophageal Adenocarcinoma
Esophageal Carcinoma
Prostate Cancer
Esophageal cancer
Gastroesophageal Junction Adenocarcinoma
Lung Cancer
Multiple Myeloma
Lymphoma
Stomach Cancer
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting2 awards Phase 3
Cemiplimab + Surgery
for Advanced Skin Cancer
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.
Recruiting2 awards Phase 37 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Huntsman Cancer Institute/University of Utah?
Huntsman Cancer Institute/University of Utah is a medical facility located in Salt Lake City, Utah. This center is recognized for care of Skin Cancer, Breast Cancer, T-Lymphoblastic Leukemia/Lymphoma, Cancer, Uterine Tumors and other specialties. Huntsman Cancer Institute/University of Utah is involved with conducting 1,129 clinical trials across 829 conditions. There are 82 research doctors associated with this hospital, such as Heloisa Soares, Michael Pulsipher, MD, Sunil Sharma, and Theresa Werner, MD.
Where is Huntsman Cancer Institute/University of Utah located?
The Huntsman Cancer Institute/University of Utah Hospital is situated at 1950 Circle of Hope Dr, Salt Lake City, UT 84112, on the University of Utah campus's northeast corner, adjacent to Primary Children’s Hospital and University of Utah Hospital. Complimentary valet parking is provided Monday through Friday, from 7:00 am to 5:30 pm.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Huntsman Cancer Institute/University of Utah hospital, contact the Billing Office at 801-587-6303 or 800-862-4937. For assistance with your bill, reach out to a financial advocate at 801-581-2957. For online billing consultations, schedule an appointment or call 801-587-6303.
What insurance does Huntsman Cancer Institute/University of Utah accept?
The Huntsman Cancer Institute/University of Utah accepts a wide range of insurance plans, such as SelectHealth Medicare Advantage, Aetna, American Health Plans, Blue Cross Blue Shield, and Cigna. SelectHealth Medicare Advantage members benefit from access to the Huntsman Cancer Institute through the SelectHealth Medicare Advantage Network Expansion. Additionally, the University of Utah Health collaborates with most major health insurance carriers and transplant networks.
What awards or recognition has Huntsman Cancer Institute/University of Utah received?
Huntsman Cancer Institute at the University of Utah is recognized as the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West, serving a broad region. It boasts a distinguished history of cancer genetics research, leveraging the Utah Population Database, the largest of its kind in the U.S., to identify genetic patterns of cancer in families. The institute leads in discovering genes for inherited cancers and operates the most extensive Phase 1 clinical cancer research program in the Mountain West, offering around 325 clinical trials.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.